Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Plus 5-FU/LV Beyond Progression on Regorafenib Monotherapy in mCRC
NCT03099486Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2017
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, fluorouracil, folinic acid in colorectal cancer (CRC), sponsored by Fox Chase Cancer Center. Started Oct 2017; status: terminated.
02
Drugs
regorafenibfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03099486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099486.